Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)
Rocket Pharmaceuticals (RCKT) reported Long-Term Investments of $34.3 million for Q4 2023, down 20.7% on a YoY basis from $43.3 million in Q4 2022, and up 18.52% sequentially from $29.0 million in Q1 2023.
Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 3 years of Long-Term Investments data on file, last reported at $34.3 million in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Investments fell 20.7% year-over-year to $34.3 million; the trailing twelve-month figure through Dec 2023 stood at $34.3 million (down 20.7% YoY), and the FY2023 full-year result was $34.3 million, down 20.7% from the prior year.
- Long-Term Investments improved to $34.3 million in Q4 2023, from $29.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $43.3 million in Q4 2022 to a low of $29.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rocket Pharmaceuticals | 357.93 Mn | 357.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 34.32 Mn |
| Mar 31, 2023 | 28.96 Mn |
| Dec 31, 2022 | 43.28 Mn |
| Dec 31, 2018 | 7.40 Mn |
| Sep 30, 2018 | 32.00 Mn |
| Jun 30, 2018 | 39.36 Mn |